Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

July 19, 2022

Study Completion Date

July 19, 2022

Conditions

Cushing SyndromeNeoplasms

Interventions

DRUG

Dabigatran Etexilate

Dabigatran will be administered orally as a 75 mg capsule on Day 1 and Day 12.

DRUG

Relacorilant

Relacorilant will be administered orally as 4 X 100 mg capsules (400 mg) on Days 3 through 13.

Trial Locations (1)

Site 01, Miami